Ranexa MERLIN Trial Could Support First-Line Angina, Acute Coronary Syndrome Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
CV Therapeutics says 5,500-patient Ranexa outcomes trial in ACS patients expected to begin in fourth quarter under a special protocol assessment with FDA. An absence of a trend towards death or arrhythmia would be sufficient for first-line chronic angina claim, firm says.
You may also be interested in...
CVT To Co-Promote Solvay's Aceon In Preparation For Ranexa Launch
CVT's 150-rep sales force will be used to promote the ACE inhibitor Aceon as well as the angina therapy Ranexa, which could launch in 2006. Aceon sales growth is tied to outcomes data expected to be added to labeling in 2005, CVT says.
CVT To Co-Promote Solvay's Aceon In Preparation For Ranexa Launch
CVT's 150-rep sales force will be used to promote the ACE inhibitor Aceon as well as the angina therapy Ranexa, which could launch in 2006. Aceon sales growth is tied to outcomes data expected to be added to labeling in 2005, CVT says.
CV Therapeutics Ranexa Benefit Over Norvasc Will Be Focus Of Additional Phase III Trial
Refractory angina trial designed under a special protocol assessment with FDA will begin in the third quarter. The company predicts a "broad restricted label" based on the study, which follows recommendations made by FDA's Cardio-Renal Drugs Advisory Committee.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: